CD40 and primary biliary cholangitis: A Phase I/II study (clinicaltrials.gov, NCT 02193360) of an anti-CD40 monoclonal antibody (FFP104; Dacetuzumab/Lucatumumab) in PBC patients was conducted to evaluate its safety, tolerability and pharmacodynamics (83).